Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 59.50 at 8:00 am ET, low 58.30 at 4:00 am ET.
the bull case· 2
3
customers naming RPRX as a supplier in their own filings
sec filingsfrom their filings+3.32%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 2
7 of 23
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '2643
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Of the 6 companies Royalty Pharma plc moves with most closely, 1 also shares its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
A rule beside a ticker marks a company that appears in both readings.
Which of these the filings never mention ›646 managers report a position worth $20.4B between them, and 43 of them hold 80% of it.
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Royalty Pharma plc
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
tall tick = annual report · 1 on record
RPRX (Royalty Pharma plc) has 6 disclosed suppliers and 3 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.